Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00343746
Other study ID # 17-00039
Secondary ID R01EY011289-15
Status Recruiting
Phase N/A
First received June 19, 2006
Last updated February 2, 2018
Start date October 2005
Est. completion date January 2020

Study information

Verified date February 2018
Source New York University School of Medicine
Contact Catherine Randall
Phone 212 263 7563
Email catherine.randall@nyumc.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. Optical Coherence Tomography may be useful for early diagnosis and monitoring of different types of eye diseases.


Description:

The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. OCT may be useful for early diagnosis and monitoring of different types of eye diseases.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date January 2020
Est. primary completion date June 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Subjects with healthy eyes, macular degeneration, glaucoma and other various eye diseases. Also must be able to fixate on target.

Exclusion Criteria:

- If the fundus is not visible if the media is opaque and if they are unwilling to participate.

Study Design


Locations

Country Name City State
United States University of Pittsburgh UPMC Eye Center Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
New York University School of Medicine National Eye Institute (NEI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. Optical Coherence Tomography may be useful for early diagnosis and monitoring of different types of eye diseases. 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A